This disclosure describes methods for regulating the biosynthesis of pimelic acid, 7-aminoheptanoate, 7-hydroxyheptanoate, heptamethylenediamine, 7-aminoheptanol, or 1,7-heptanediol by channeling increased flux through the biosynthesis pathway to obtain an intermediate required for growth of the host microorganism.

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.

Disclosed herein is a method of reducing an aromatic nitro compound. In some embodiments the method comprises the step of contacting an aromatic nitro compound with a catalyst, wherein, the catalyst comprises, a disproportionation agent, and a biocatalyst. Also disclosed is a biocatalyst for use in the method, use of a disproportionation agent, and a biocatalyst, as a catalyst for reducing an aromatic nitro compound, and a kit comprising a disproportionation agent, and a biocatalyst.

The invention relates to methods for identifying polypeptides and polynucleotides of interest, be they novel or variant polypeptides and polynucleotides, by expressing a plurality of polypeptides in an obligate or facultative anaerobe that is incapable of, or displays a reduction in, the oxidation of NADH and/or NADPH under anaerobic fermentation conditions and selecting an obligate or facultative anaerobe that grows or displays a growth advantage under said conditions. The invention is also concerned with novel enzymes per se, and their use in enzymatic production processes.

This disclosure describes methods for regulating the biosynthesis of pimelic acid, 7-aminoheptanoate, 7-hydroxyheptanoate, heptamethylenediamine, 7-aminoheptanol, or 1,7-heptanediol by channeling increased flux through the biosynthesis pathway to obtain an intermediate required for growth of the host microorganism.

Cells and cell cultures are provided that have improved tolerance to 3-hydroxypropionic acid (3HP). Genetic modifications to provide a mutated or overexpressed SFA1 gene or other enhancement of 3HP detoxification via a glutathione-dependent dehydrogenase reaction, including medium supplementation with glutathione, may be combined with a 3HP producing metabolic pathway.

This disclosure describes methods for regulating the biosynthesis of pimelic acid, 7-aminoheptanoate, 7-hydroxyheptanoate, heptamethylenediamine, 7-aminoheptanol, or 1,7-heptanediol by channeling increased flux through the biosynthesis pathway to obtain an intermediate required for growth of the host microorganism.

Disclosed herein is a method of reducing an aromatic nitro compound. In some embodiments the method comprises the step of contacting an aromatic nitro compound with a catalyst, wherein, the catalyst comprises, a disproportionation agent, and a biocatalyst. Also disclosed is a biocatalyst for use in the method, use of a disproportionation agent, and a biocatalyst, as a catalyst for reducing an aromatic nitro compound, and a kit comprising a disproportionation agent, and a biocatalyst.